Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 19 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 2
6(50.0%)
N/A
4(33.3%)
Phase 1
1(8.3%)
Phase 3
1(8.3%)
12Total
Phase 2(6)
N/A(4)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials
NCT07342335Recruiting

Breaking Barriers to Research Access

Role: lead

NCT07503717Not ApplicableRecruiting

SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Central Nervous System Surveillance Versus No Surveillance

Role: collaborator

NCT07432932Recruiting

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

Role: collaborator

NCT03096093Phase 1Active Not Recruiting

Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer

Role: collaborator

NCT07335120Recruiting

A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma

Role: lead

NCT02505750Phase 3Active Not Recruiting

Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma

Role: collaborator

NCT04697394Completed

CITRuS Stage 1; Feasibility

Role: collaborator

NCT06169163Recruiting

Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms

Role: collaborator

NCT04268888Phase 2Suspended

Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC

Role: lead

NCT04487587Phase 2Active Not Recruiting

A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer

Role: lead

NCT03721757Phase 2Completed

CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer

Role: lead

NCT04603105Active Not Recruiting

CCP Cancer UK Companion Study

Role: lead

NCT04622761Phase 2Not Yet Recruiting

Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome

Role: lead

NCT03215459Unknown

Cardiopulmonary Exercise Testing: An Assessment of Patients Fitness for Palliative Chemotherapy for Pancreatic Cancer

Role: lead

NCT04270890Not ApplicableUnknown

Investigation of an Abdominal Compression Device

Role: lead

NCT04275921Not ApplicableUnknown

Magnetic Resonance Imaging for Lung Radiotherapy

Role: lead

NCT03610100Phase 2Suspended

Acelarin First Line Randomised Pancreatic Study

Role: lead

NCT01551459Phase 2Completed

A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma

Role: lead

NCT02125175Not ApplicableCompleted

BIOPROP20: Biologically Optimised IMRT for Prostate Radiotherapy Hypofractionated Radiotherapy With Intra-prostatic Boosts to Tumour Nodules in Men With Intermediate and High Risk Prostate Cancer

Role: lead

All 19 trials loaded